Is Semax legal? FDA status, the July 2026 vote and what the evidence shows

The short version. Semax is not FDA approved and is not on the 503A Bulks List. An advisory committee voted for listing it on 24 July 2026, a recommendation the FDA is not bound by. FDA staff recommended against, citing insufficient evidence of effectiveness, no human pharmacokinetic data and quality concerns.

What is Semax?

Semax is a synthetic seven amino acid peptide, Met-Glu-His-Phe-Pro-Gly-Pro. The FDA briefing document prepared for the July 2026 Pharmacy Compounding Advisory Committee describes it as an analogue of ACTH 4-10, a fragment of adrenocorticotropic hormone, with a Pro-Gly-Pro tail added for stability. It was developed in Russia, where it is registered as a medicine and sold as 0.1% and 1% nasal drops. In the US it is marketed online as a nootropic and for a long list of conditions the FDA catalogued, from anxiety and ADHD to stroke recovery, ALS and Alzheimer's disease. Those claims come from sellers and clinics, not from an approval.

Semax has the same naming problem as several peptides in the July review. The FDA says the nominators did not make clear whether they meant Semax free base or Semax acetate, which are different active ingredients, so the agency evaluated both on its own initiative and asked the committee two separate questions. None of the US websites the FDA searched said which form they sold. The FDA Law Blog also reported a concern raised at the meeting that the name could be confused with semaxanib, an unrelated compound. A product called Semax is not a guarantee of one specific molecule.

In plain EnglishSemax is a short lab-made piece modelled on a fragment of a natural hormone. Russia sells it as nasal drops. In the US it is not an approved drug, and products sold under the name may not all be the same substance.

Is Semax legal in 2026?

Semax's legal position rests on three dated facts. First, there is no FDA approved Semax product, and a Russian registration does not change that. Second, Semax is not on the 503A Bulks List, and the FDA page on 503A bulk substances, current as of 14 May 2026, does not name it. Third, the FDA safety-risk page, current as of 22 April 2026, lists "Semax (heptapeptide)" among substances that were nominated but withdrawn, noting possible immunogenicity and that the agency lacks sufficient information to know whether it would cause harm. That takes Semax out of the interim categories, not into Category 1. A February 2026 statement by HHS Secretary Robert F. Kennedy Jr. about moving peptides back to Category 1 was a statement, not an agency action.

The committee vote is the fact most often misreported. On the afternoon of 24 July 2026 the committee voted on Semax free base and Semax acetate, and law firm McDermott Will & Schulte and the FDA Law Blog both reported the result as 8 in favour, 5 against and 1 abstention. The FDA's own briefing states that it will not issue a final determination until the advisory process is considered and all reviews are finalised, and adding a substance to the list requires rulemaking. As of 6 October 2026 the FDA meeting page carried no posted minutes and the agency had published no final determination. A page that calls Semax "now legal to compound" is describing a rule that does not exist yet.

In plain EnglishA committee said yes by three votes. The FDA has not acted on it. Until it does, Semax is in the same legal position it was in before the vote.

Semax is registered as a medicine in Russia. In the US, FDA staff found insufficient evidence that it works and no human pharmacokinetic study by any route.

The Ozemback peptide legal status tracker carries Semax in the "recommended, not law" group alongside BPC-157, TB-500, KPV, MOTS-c and Epitalon, with the date of each fact. Semax was one of six peptides the committee backed across the two-day July 2026 meeting, and emideltide was the only one voted down. The tracker will change the Semax row on the day the FDA proposes or finalises a rule, because that is the event that would alter its legal status. For how the committee overrode its own staff across the meeting, see our analysis of the vote. To test what you know, try the approved, recommended or neither quiz.

What does the evidence for Semax show?

The FDA's conclusion: insufficient evidence of effectiveness for cerebral ischemia, migraine or trigeminal neuralgia, and no human pharmacokinetic study by any route.

The FDA reviewed Semax for the uses the nominators proposed: cerebral ischemia, migraine and trigeminal neuralgia. "Nootropic" was also nominated, and because it has no diagnostic code the FDA folded it into the cerebral ischemia review; ADHD was not evaluated because no supporting literature was found. The nominators submitted 38 articles, and none described a compounded Semax product. For cerebral ischemia the only submitted human source was a conference abstract with an unstated number of patients and no clinical outcomes reported. Most other human studies were published in Russian without full English text, and the FDA did not consider those. Its overall finding was that the available references were few, small, lacked study detail and did not demonstrate effectiveness.

Across everything it reviewed, the FDA counted Semax given to 33 to 47 healthy adults, 69 adults with medical conditions and 451 children with depression or tic disorders, all by nasal route. Three of those references were meeting abstracts without full studies, and in several Semax was given alongside other drugs or therapies, which makes its own contribution hard to separate. The FDA found no study of Semax given by subcutaneous injection, one of the two routes the nominators proposed. In animals the picture is broader: rodent studies report neuroprotective, antithrombotic, analgesic and anxiolytic-like effects through mechanisms the FDA calls poorly understood. Rodent findings are not evidence that the same happens in people.

In plain EnglishSemax has been given to a few hundred people in small, mostly Russian studies, almost all as nose drops. The FDA looked at what it could read and concluded it does not show Semax works for the uses proposed.

What has been reported on safety

The FDA's safety conclusion is that there is insufficient clinical information to characterise Semax's safety profile. Its FAERS search through 3 December 2025 returned one report: a consumer who described eye pain and burning after using Semax 0.1% nasal drops bought online, with hospitalisation reported and the pain unresolved a year later. Most published studies did not discuss adverse events at all. The FDA raised three specific concerns: a possible bleeding risk, because one study discussed antithrombotic properties; immunogenicity from aggregates and peptide impurities when injected or sprayed; and a finding in mice that Semax potentiated amphetamine-induced dopamine release, with no toxicity studies identified to assess abuse potential. One report in a database is not evidence of safety, as the FDA notes compounders generally do not report adverse events.

What is the Semax dosage?

There is no FDA approved dose of Semax, because there is no FDA approved product.

Every Semax dose figure you will find in the US comes from somewhere other than a US label. The small studies the FDA reviewed used widely varying amounts and schedules, often in conference abstracts that omitted study details, and none were designed to establish a dose. The FDA found US websites selling injectable and nasal spray products in several strengths, some labelled "for research purposes only", and none stating whether they contained the free base or a salt. No outsourcing facility has reported compounding Semax since 2019. We report this because it is the record, and we do not publish a recommended dose, schedule or protocol for Semax or any other compound.

What is still unknown about Semax?

• Whether it works for anything in a well-designed trial. The FDA found insufficient evidence for every use it reviewed.
• How the body handles it. The FDA found no human pharmacokinetic study by any route.
• Whether injection is safe. No human data exist for the subcutaneous route.
• Abuse potential and bleeding risk. Both were flagged from animal and early human findings, and neither has been studied properly.
• What is in a given product. Sellers do not say which form they sell, and the FDA found public certificates of analysis lacked key tests, including endotoxin.
• Whether the FDA will follow the committee. The agency is not bound by the July 2026 vote, and no rule had been proposed as of 6 October 2026.

How should you read other pages about Semax?

Check whether the page treats a Russian registration as if it were a US approval; it is not. Check whether it reports the July 2026 vote as a recommendation or as a change in the law; only the first is accurate. Check whether the studies it cites were done by nasal route, in what population, and whether you can open them in a language you read. Check who pays the author: nearly every site ranking for Semax benefits or dosage sells it, sells a consultation or links to a seller, and many pair it with Selank as a bundle. This page carries a date at the top, 6 October 2026, so you can tell when it stops being current. Related files: TB-500 and BPC-157, reviewed by the same committee.

The questions people actually type

Sources